[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"experimental-pain-in-healthy-human-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:experimental-pain-in-healthy-human-participants":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100626381","early-phase-1-repeated-cbd-administration-and-cannabis-outcomes-100626381",false,"NCT07434895","Repeated CBD Administration and Cannabis Outcomes","The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study","Inclusion Criteria:\n\n* English-speaking, literate adults,\n* Male or female,\n* Between the ages of 18-55,\n* Body Mass Index from 18.5-32.0 kg\u002Fm2,\n* Not currently seeking treatment for cannabis or drug use,\n* Able to provide written informed consent and perform all study procedures,\n* If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n* Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and\n* Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.\n\nExclusion Criteria:\n\n* Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n* Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n* Current or past history of major psychiatric disorder that would limit ability to participate in the study,\n* Use of cannabis exclusively for medical reasons (no recreational use reported),\n* Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),\n* Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,\n* Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n* Clinically significant abnormal laboratory findings,\n* History of seizure disorder,\n* Clinically significant history of head injuries requiring medical management or long lasting sequalae, and\n* Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).",true,"ALL","18 Years","55 Years",{"count":21,"type":22},23,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.",[28,29,30],"Cannabis","Abuse Liability","Experimental Pain in Healthy Human Participants",[32,33,34],"marijuana","cannabidiol (CBD)","marijuana users","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":22},"2026-06-29",{"date":43,"type":22},"2029-12-01",{"name":45,"class":46},"Hannah Harris","OTHER"]